Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Company Overview

Anthera Pharmaceuticals, Inc. was a biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs, particularly in the cardiovascular, inflammatory and autoimmune fields. The company operated as a development-stage business rather than a diversified commercial pharmaceutical manufacturer.

Anthera’s product candidates included varespladib, an inhibitor of secretory phospholipase A2 that was studied for cardiovascular and acute coronary syndrome indications, and Sollpura, also known as liprotamase. Sollpura was an oral pancreatic enzyme replacement therapy investigated for exocrine pancreatic insufficiency, including conditions associated with cystic fibrosis and chronic pancreatitis. The company also pursued blisibimod, an investigational treatment aimed at autoimmune diseases such as systemic lupus erythematosus.

Anthera’s development programs produced mixed clinical results, and the company subsequently reduced operations and evaluated strategic alternatives after setbacks involving its lead candidates. The company was formerly listed on the Nasdaq under the symbol ANTH and later traded over the counter. Because Anthera’s business was centered on discontinued or unsuccessful drug-development programs, reliable information about current operations, products and leadership is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 42 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ANTH
• CIK: 1316175
• Web: www.anthera.com
• Phone: (410) 350-1839
• Fax: 510-856-5597
• Employees: 20
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.49